New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:16 EDTNBIXNeurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:16 EDTNBIXCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
07:20 EDTNBIXCowen to hold a conference
Subscribe for More Information
February 23, 2015
10:41 EDTNBIXNeurocrine management to meet with Piper Jaffray
Subscribe for More Information
February 19, 2015
07:07 EDTNBIXNeurocrine 6.944M share Secondary priced at $36.00
Subscribe for More Information
February 17, 2015
18:36 EDTNBIXOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTNBIXNeurocrine files to sell $225M in common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use